ArticleNeuropathology and applied neurobiology2026
Evaluating Basigin as a Potential Biomarker of Blood-Brain Barrier Dysfunction in Cerebral Amyloid Angiopathy.
Article in Neuropathology and applied neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
aimsBlood-brain barrier (BBB) dysfunction may be involved in the pathophysiology of neurodegenerative disorders, including sporadic cerebral amyloid angiopathy (CAA). Because basigin (BSG) may induce activity of matrix metalloproteinases and thereby BBB breakdown, we investigated BSG expression in CAA brain tissue with immunohistochemistry and as cerebrospinal fluid biomarker for BBB dysfunction in patients with CAA.
methodsUsing immunohistochemistry, we quantified BSG expression within the cortical microvasculature of the temporal lobe of 50 CAA patients (16 with intracerebral haemorrhage [CAA-ICH] and 34 without intracerebral haemorrhage [CAA-NH]) and 35 controls. To investigate whether BSG is expressed at another brain barrier, choroid plexus tissue was qualitatively assessed. Additionally, we compared cerebrospinal fluid levels of BSG between 40 CAA patients and 27 healthy controls using ELISA.
resultsCortical vessels, in particular capillaries, were positive for BSG. Median %area of BSG expression was increased in CAA cases (1.02%, IQR [0.63-1.68]) compared with controls (0.65%, IQR [0.43-1.01], p = 0.013). Moreover, we observed more BSG staining in CAA-NH (1.23%, IQR [0.90-2.0]) than in CAA-ICH (0.58%, IQR [0.24-1.00], p = 0.001) and controls (p < 0.001). Choroid plexus epithelial cells showed apical BSG expression, whereas endothelial cells were negative. The median BSG concentration in CSF was decreased in CAA (11.0 ng/mL, IQR [10.1-13.8]) compared with controls (13.00 ng/mL, IQR [11.5-14.5], p = 0.02).
conclusionsCSF concentrations of BSG may be related to altered expression at the BBB; the BSG concentrations in CSF may thus serve as a biomarker of BBB function, although a contribution of choroid plexus epithelial BSG cannot be entirely excluded. Independent cohorts are needed to replicate these observations before we can conclude that reduced CSF concentrations of BSG may indicate an alteration of the BBB in patients with CAA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.